SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : RXSD Rexall Sundown

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dorine Essey who wrote (80)9/24/1998 5:02:00 PM
From: Anthony Wong   of 327
 
The following article explains the weakness in the nutraceutical sector:

09/18 15:34 RESEARCH ALERT - HSBC starts TwinLab as accumulate

NEW YORK, Sept 18 (Reuters) - HSBC Securities has started coverage of
TwinLab Corp. <TWLB.O> with an "ADD" rating, the firm said Friday.

This rating, which is one step below buy, could be called accumulate, a
spokeswoman explained.

The stock was holding onto a two point gain, at 34-5/8 in the final hour of
trading Friday, after reaching an intraday high of 34-1/8,

-- HSBC describes Hauppauge, N.Y., based Twinlab as a manufacturer and
marketer of vitamins, minerals, and nutritional supplements. The company is
part of the nutraceutical industry which had estimated 1997 U.S. revenues of
roughly $10 billion and is growing at a compound annual growth rate of 15-20
percent, the firm noted.

-- It said the major players in the nutraceutical industry are TwinLab, NBTY
Inc's <NBTY.O> Nature's Bounty, Rexall Sundown Inc. <RXSD.O>, General
Nutrition Cos Inc. <GNCI.O> and Weider Nutrition International Inc
.<WNI.N>. "Combined, these companies accounted for $1.95 billion in annual
revenue in 1997, or approximately 20 percent of the domestic nutritional
supplement market.

-- TwinLab and many of its competitors experienced a steep decline in stock
prices in the past two months, prompted by GNC's announcement regarding
margin pressures, HSBC said.

-- It pointed out the decline came at a point where the industry was demanding
high multiples
, adding TwinLab is now trading at 20.1 times estimated 1999
earnings of $1.62 per share, down from a high of 28x in June.

-- The firm said pricing pressure from GNC should not have a significant impact
on TwinLab, as GNC accounts for only 10 percent of the company's revenue,
and currently TwinLab has been expanding its distribution through mass market
retailers.

-- It said TwinLab experienced strong revenue growth of 57 percent during the
first half, due in part to its association with Wal-Mart Stores Inc. <WMT.N>,
and is expected to maintain a long-term growth rate of 25 percent per year.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext